Compare Capri Holdings Ltd (CPRI) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capri Holdings Ltd vs Sana Biotechnology Inc — how do they compare? Capri Holdings Ltd trades at $15.62 (market cap $1.75B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Capri Holdings Ltd is the larger of the two by market cap, and Sana Biotechnology Inc is trading nearer its 52-week high, Capri Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| CPRI | SANA | |
|---|---|---|
Market Cap | $1.75B | $1.13B |
Sector | Consumer Staples | Health |
52-Week High | $27.66 | $5.92 |
52-Week Low | $14.98 | $2.68 |
Enterprise Value | $3.03B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Capri Holdings (CPRI) trades at $15.66, down 65% over five years and near 52-week lows after recent analyst downgrades. The stock shows bearish technical signals with neutral oscillators but faces fundamental challenges including declining revenue from $5.7B in 2022 to $4.4B in 2025 and a net loss of $1.18B last year. Recent Q1 2027 earnings beat expectations with $0.67 EPS versus $0.41 expected, driven by margin improvements and Jimmy Choo growth, though management cut full-year revenue guidance citing Michael Kors weakness.
The investment case hinges on successful execution of the post-Versace turnaround strategy, with the stock trading below consensus price targets offering potential upside if Michael Kors stabilizes. However, significant risks remain including ongoing revenue declines, luxury market softness, and high debt levels requiring careful monitoring of quarterly execution against revised guidance.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
